At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET
Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue. The company highlighted progress in its registrational myositis trial (data mid-2027, BLA 2H27) and plans to initiate a second registrational cohort in SSc-ILD in 4Q26. Cash position strengthened to $225.1M post a $150M May offering, extending runway into mid-2027, but the EPS beat is modest and pipeline milestones remain distant, making this a neutral event.
- Q2 2026 EPS of -$0.34 beat consensus of -$0.37 by 8.1%
- Cash, cash equivalents, and short-term investments were $225.1M as of June 30, 2026, up from $133.6M at year-end 2025
- Registrational RESET-Myositis data expected mid-2027 with BLA submission in 2H27
- SSc-associated ILD registrational cohort of ~25 patients expected to initiate in 4Q26
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access